NORDIC BIOSCIENCE A/S Patent applications |
Patent application number | Title | Published |
20160123993 | Collagen Type X Alpha-1 Assay - An antibody specifically reactive with an epitope of collagen type X alpha 1 comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1), and a method of immunoassay for detecting in a biological sample an epitope comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1) of collagen type X alpha 1, by contacting said biological sample with said antibody, and determining the amount of binding of said antibody. | 05-05-2016 |
20160091502 | TEXT NOT AVAILABLE - Methods of diagnosis or of quantitation of fibrosis are provided that comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of the measure in the patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a contacting protein fragments naturally present in the sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to the immunological binding partner to measure therein protein fragments comprising the neo-epitope. The protein is collagen type III, collagen type I, collagen type IV, collagen type V, elastin, biglycan, decorin, lumican, versican, perlecan, neurocan, brevican, fibromodulin, serglycin, syndecan, betaglycan, vimentin, or C-reactive protein. | 03-31-2016 |
20160077108 | Collagen Type VI Alpha-1 Assay - Provided is an antibody which binds to an epitope of collagen type VI alpha 1 comprised in the N-terminal globular domain internal amino acid sequence -ADWGQSRDAEEAISQ- (SEQ ID NO: 1). Also provided is a method of immunoassay for detecting in a biological sample an epitope comprised in the N-terminal globular domain internal amino acid sequence -ADWGQSRDAEEAISQ- (SEQ ID NO: 1) of collagen type VI alpha 1, by contacting the sample with the antibody, and determining the amount of binding of the antibody. | 03-17-2016 |
20160061844 | PIIINP Neo-epitope Assay - Provided is a monoclonal antibody specifically reactive with a C-terminal neo-epitope of PIIINP comprised in a C-terminal amino acid sequence CPTGXQNYSP-COOH (SEQ ID NO: 4) in which X is Gly or Pro, and where the monoclonal antibody does not recognise or bind an elongated version of the C-terminal amino acid sequence CPTGXQNYSPQZ-COOH (SEQ ID NO: 5), in which Z is absent or is one or more amino acids of the sequence of collagen type III. Also provided is a method of immunoassay for detecting in a biological sample the C-terminal neo-epitope of PIIINP generated by N-protease cleavage of intact type III procollagen, by contacting the sample with the monoclonal antibody, and determining the amount of binding of the antibody. | 03-03-2016 |
20130260400 | ASSAY FOR A TYPE II COLLAGEN BIOMARKER - An assay for Type II collagen fragments in serum, plasma, or synovial fluid obtains a quantitative measure of the concentration of all protein fragments in a serum, plasma, or synovial fluid sample that are reactive with an antibody, or immunoreactive antibody fragment, having specific reactivity with a C-terminal epitope present in the amino acid sequence GPPGRDGAAG and lacking specific reactivity with an amino acid sequence comprising the amino acid sequence GPPGRDGAAGV, which may be Mab NB44-3C1 as produced by the cell line deposited in HPA Culture Collection Logistics Office with Accession Number 10091402. | 10-03-2013 |
20130079295 | TREATMENT OF CARTILAGE RESORPTION - Excessive articular cartilage degradation is treated or prevented by administration to a mammal such as a human | 03-28-2013 |
20120046224 | TREATMENT OF DIABETES AND METABOLIC SYNDROME - Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating insulin resistance, and for reducing serum glucose levels. | 02-23-2012 |
20120045781 | PATHOLOGY BIOMARKER ASSAY - Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described. | 02-23-2012 |
20100323377 | BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT - A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events. | 12-23-2010 |
20100317023 | BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT - A method of diagnosis of cardiovascular disease (CVD) an immunoassay to measure aggrecan fragments in said sample, and association of an elevation above a normal level with the presence of CVD, is conducted by contacting aggrecan fragments in said sample with an first antibody reactive with an N-terminal first epitope formed by cleavage of aggrecan by a proteinase and with a second antibody reactive with a second aggrecan epitope which is present in aggrecan at a location in the C-terminal direction from the location of said N-terminal epitope, and measuring the extent of simultaneous binding of both antibodies. | 12-16-2010 |
20100209940 | FIBROSIS BIOMARKER ASSAY - Methods of diagnosis or of quantitation of fibrosis comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a method comprising: | 08-19-2010 |
20090216094 | Method of deriving a quantitative measure of a degree of calcification of an aorta - A method of deriving a quantitative measure of a degree of calcification of a blood vessel such as an aorta by processing an image such as an X-ray image of at least a part of the blood vessel containing said calcification comprises: taking a starting set of digital data representative of an image of at least part of a blood vessel containing a calcification set against a background; estimating the boundary of the calcification; using inpainting to replace digital data in said starting set representing the calcification with data extrapolating the boundary of the background to extend over the area of calcification, and so generating an inpainted set of digital data; and computing the difference between the starting set of digital data and the inpainted set of digital data to obtain a quantitative measure of the degree of calcification of the blood vessel. | 08-27-2009 |
20090190815 | Cartilage Curvature - A method for the analysis of three dimensional scan data representing an articular cartilage is provided to extract a quantitative parameter indicative of joint pathology. A measure of local curvature of the cartilage is determined within a region of interest. The value of the quantitative parameter of this joint derived from this measure is compared with the value of a similar quantitative parameter previously established in respect of healthy joints and/or joints characterised by a pathology. | 07-30-2009 |